Roanna Ruiz
Stock Analyst at Leerink Partners
(0.58)
# 3,744
Out of 4,818 analysts
62
Total ratings
23.68%
Success rate
-22.18%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $5 → $6 | $4.28 | +40.19% | 5 | Mar 7, 2025 | |
| CRMD CorMedix | Initiates: Outperform | $18 | $9.15 | +96.72% | 1 | Mar 7, 2025 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Market Perform | $1 | $0.70 | +42.17% | 1 | Mar 4, 2025 | |
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $6.29 | +217.97% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $14.60 | +84.93% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $2.85 | +356.14% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $5.03 | +178.61% | 1 | Apr 5, 2024 | |
| UTHR United Therapeutics | Initiates: Outperform | $330 | $296.42 | +11.33% | 1 | Feb 5, 2024 | |
| CYTK Cytokinetics | Initiates: Outperform | $58 | $40.35 | +43.76% | 1 | Aug 15, 2023 | |
| CORT Corcept Therapeutics | Initiates: Market Perform | $25 | $71.79 | -65.18% | 1 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | $49 | $5.52 | +788.49% | 10 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $13 | $2.50 | +420.00% | 7 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $2.84 | +111.27% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $17.47 | +8.76% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $103.64 | +15.79% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $5.79 | +763.56% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $40 | $11.18 | +257.78% | 6 | Oct 19, 2022 |
Xeris Biopharma Holdings
Mar 7, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $4.28
Upside: +40.19%
CorMedix
Mar 7, 2025
Initiates: Outperform
Price Target: $18
Current: $9.15
Upside: +96.72%
Lexicon Pharmaceuticals
Mar 4, 2025
Downgrades: Market Perform
Price Target: $1
Current: $0.70
Upside: +42.17%
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $6.29
Upside: +217.97%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $14.60
Upside: +84.93%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $2.85
Upside: +356.14%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $5.03
Upside: +178.61%
United Therapeutics
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $296.42
Upside: +11.33%
Cytokinetics
Aug 15, 2023
Initiates: Outperform
Price Target: $58
Current: $40.35
Upside: +43.76%
Corcept Therapeutics
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $71.79
Upside: -65.18%
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $5.52
Upside: +788.49%
Jan 27, 2023
Maintains: Outperform
Price Target: $12 → $13
Current: $2.50
Upside: +420.00%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $2.84
Upside: +111.27%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $17.47
Upside: +8.76%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $103.64
Upside: +15.79%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $5.79
Upside: +763.56%
Oct 19, 2022
Maintains: Market Perform
Price Target: $60 → $40
Current: $11.18
Upside: +257.78%